Q-omics provides the consensus-scored HTN3 profile across patient tissues and cancer cell-line models. HTN3 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, HTN3 is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, HTN3 RNA expression shows 4,118 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BRCA, HNSC, and STAD as cancer lineages where HTN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HTN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HTN3 survival associations across molecular data types. HTN3 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HTN3 RNA expression–survival associations across cancer types. High HTN3 expression shows unfavorable associations in BRCA, COAD, UVM, MESO, READ and BLCA. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for HTN3 RNA expression.
This table summarizes HTN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for HTN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HTN3 shows lower tumor expression in HNSC and higher tumor expression in LUSC and LIHC. The HNSC box plot shows higher HTN3 RNA expression in normal versus tumor tissue (log2 FC = −2.688, t-test p = .002).
This table shows molecular features associated with HTN3 in patient tissues and cancer cell lines. In patient samples, HTN3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, HTN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LUNG_NSCLC_LUAD.
